OS rate and NNT per additional overall survivor
tumor, melanoma
TUMOR, MELANOMA, ULCERATION
Due to the rapidly evolving treatment landscape, patients included in the two trials likely had access to different therapeutic options post-recurrence. To account for higher post-recurrence survival due to improved subsequent treatments for advanced melanoma in CheckMate 238 compared with EORTC 18,071, the analysis of OS was conducted with adjustment of the post-recurrence survival in the placebo arm of EORTC 18,071 under a partitioned-survival framework. The adjusted post-recurrence survival in the placebo arm of EORTC 18,071 represented the potential post-recurrence survival if the post-recurrence treatment options in the CheckMate 238 had been available during the conduct of EORTC 18,071 (online supplemental Fig. Sample selection prior to pooling EORTC 18,071 and CheckMate 238 data. Thirty-eight patients with missing tumor ulceration status were excluded from EORTC 18,071; 60 patients were excluded from CheckMate 238 due to missing values (15 had missing tumor ulceration status; 36 had missing lymph node involvement status; 7 had missing baseline LDH status; 1 patient had missing tumor ulceration and lymph node involvement status; and 1 patient had missing lymph node involvement and baseline LDH status). 